* Intra-Cellular Therapies Inc ITCI.OQ reported a
quarterly
adjusted loss of 16 cents per share for the quarter ended in
March, higher than the same quarter last year, when the company
reported EPS of -46 cents. The mean expectation of
fourteen analysts for the quarter was for a loss of 32 cents per
share. Wall Street expected results to range from -47 cents
to -24 cents per share.
* Revenue rose 52% to $144.87 million from a year ago;
analysts
expected $141.38 million.
* Intra-Cellular Therapies Inc's reported EPS for the
quarter was
a loss of 16 cents.
* The company reported a quarterly loss of $15.25 million.
* Intra-Cellular Therapies Inc shares had risen by 2.6% this
quarter and lost 0.9% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 3.3%
in the last three months.
* In the last 30 days, two analysts negatively revised
earnings
estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 15 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"
Wall Street's median 12-month price target for Intra-Cellular
Therapies Inc is $91.00
This summary was machine generated from LSEG data May 7 at 01:32
p.m. UTC. All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.32 -0.16 Beat
Dec. 31 2023 -0.44 -0.30 Beat
Sep. 30 2023 -0.57 -0.25 Beat
Jun. 30 2023 -0.59 -0.45 Beat